Latest news with #Delve
Forbes
3 days ago
- Business
- Forbes
Six Ways AI Will Transform Expertise: What It Means For Firms
Jeff Berkowitz leads advisory firm Delve Research & AI platform Delve, helping organizations navigate complex policy & reputational issues. Business leaders everywhere are wondering how AI will change the way their teams work. For my company, this wasn't an abstract question—it was an opportunity to solve a major pain point. As a research and intelligence firm serving public affairs teams, our job is to catch the developments that cause reputational damage and regulatory risk. So you can imagine how crazy our day to day has been these past few years. Yet the tools available to handle the deluge of information confronting our clients were stuck in the past, with keyword‑driven systems that buried teams in noise rather than helping them see what mattered. Until generative AI. After GPT-3.5 arrived, we went deep. We built a new AI platform to solve the problems in our industry that no one else had cracked, and along the way, we learned what it takes to evolve mission‑critical knowledge work in the AI era. You don't need to build a platform to thrive in this new reality, but you do need to understand how AI is reshaping the knowledge work of many in professional services, what it means for your people and processes and how to adapt so your firm can thrive. Here are six lessons I've learned to help you navigate the future of work. Your value can't be measured only by the outputs you deliver. As AI advances, firms that measure their worth by the quantity of deliverables produced are at risk of being commoditized. But it doesn't have to be this way. No one hires top-tier consultants for their engaging slide decks or a skilled law firm for access to statutes and case law. They hire them for expertise, foresight and confidence in complex situations. AI can handle drafting and processing, but firms must deliver value beyond outputs, helping clients act decisively where stakes are high. To stay competitive, firms must deliver higher-order strategic value and judgment that AI cannot replicate. AI isn't just a tool—it's a teammate (and soon, a team of teams). AI is evolving beyond simple workflow automations and chatbot conversations into something more transformative. This doesn't mean workers will be replaced. Instead, AI is more of an Iron Man suit than a replacement robot, empowering each employee to tackle higher-level work. Smart firms will pair workers with AI teammates, shifting employees from the execution of tasks to the orchestration of systems that leverage human and machine's best contributions. Firms should consider how new AI capabilities will fit into their organizational structure, not just their workflows. AI won't replace junior talent, it will help them grow. The question on every professional services leader's mind: If AI can generate first drafts and basic analysis, do we need junior staff? And if not, how do we build the next generation of talent? The reality is that junior roles won't disappear, but they will change. Team members will need to add 'wins above replacement,' to borrow from the movie Moneyball. Juniors who copy and paste AI outputs won't last, but those who learn to orchestrate AI effectively will thrive. Meanwhile, more senior staff will have greater bandwidth to help juniors hone their judgement and instincts. Before AI, many firms relied on informal, on‑the‑job shadowing and hoped hires 'figured it out.' Now, that can get more formal. Having a structured program in place gave our firm a major advantage in training our team and the AI itself to work to our high standards. View AI as an opportunity to reshape junior roles and future-proof your team. Start with your workflows, not the tools. Resist the temptation to test 'cool' new tools in a vacuum or hope legacy platforms bolt on enough AI to keep up. Instead, ask: Where can AI truly make us better? Pinpoint specific pain points in your workflows. For example, we saw how keyword-driven monitoring platforms buried our team in noise, so we built AI systems that mirror how our analysts identify what matters. Don't start with the shiny object. Map your workflows, find the bottlenecks, and implement AI where it truly amplifies your strengths. Codify how you think and work. Your edge isn't just smart people; it's the systems and approaches they use to deliver consistent value. Now is the time to capture the processes and reasoning that make your team effective and translate them so AI can scale that expertise. Without codifying how your team works, you'll be left competing on speed and price. AI can't mirror your expertise unless you first understand, document and teach it how you think and work. Leverage your data and domain expertise. Alongside your processes, two other assets can make your AI adoption powerful: proprietary data and domain-specific expertise. Most firms hold unique data—like our years of proprietary research outputs—that can be used to inform AI in ways no one else can. Second, your domain knowledge informs which public (but often hard-to-access) datasets matter to your clients. Consumer tools like ChatGPT, for example, can't systematically access legislative, regulatory or stakeholder data—and certainly won't enrich it to match our standards for precise and comprehensive recall. Our company delivers results that consumer LLMs can't match by combining proprietary research outputs with these domain-specific datasets. Use your unique data and expertise to inform AI so your offerings remain differentiated and defensible. Conclusion: The future of expertise isn't speed; it's elevation. AI doesn't just make work faster; it frees space for critical deep work. Stress-testing assumptions, building relationships and advising on high-stakes decisions are what truly set professional services firms apart. What used to get squeezed by the pace of deliverables can now move center stage. AI is going to transform knowledge work. The winners of this AI revolution won't be the firms blindly chasing tools or pretending nothing's changing. They'll understand what makes them valuable and use AI to amplify it, not automate around it. That's the opportunity ahead for every professional services leader ready to evolve. Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?
Yahoo
23-07-2025
- Business
- Yahoo
21-year-old MIT dropouts raise $32M at $300M valuation led by Insight
Karun Kaushik and Selin Kocalar weren't planning to raise a Series A so soon. Their AI compliance startup, Delve, which announced a $3 million seed round in January, was growing fast and signing customers at a steady clip. Then, inbound interest started rolling in, COO Kocalar told TechCrunch. Delve, which automates regulatory compliance with AI agents, ended up fielding multiple term sheets, eventually closing a $32 million Series A at a $300 million valuation. The round was led by Insight Partners, which took up most of the round, with participation from CISOs at Fortune 500 companies. Insight has been 'amazing to work with, and we felt they were the right long-term partner for us,' said the COO. Delve's new valuation represents a roughly 10x jump from its previous round. Similarly, its customer base has grown from the 100 companies it reported back in January to over 500, many of them fast-growing AI startups like recently minted AI unicorn Lovable, Bland, and Wispr Flow. And while the 2-year-old company, made up of AI researchers from MIT, Stanford, and Berkeley, has seemingly struck gold by using AI to eliminate hundreds of hours of manual processes, its story began much differently. Kaushik and Kocalar met as classmates during their freshman year at MIT. Both had deep interests in AI and health tech. Kaushik had already scaled a COVID diagnostic system to thousands of users during the pandemic. In 2023, they began working on an AI-powered medical scribe to help doctors handle patient documentation. However, handling sensitive healthcare information meant they quickly encountered the costly and time-consuming world of HIPAA compliance. Instead of continuing with the medical scribe, they started building tools to help other companies get HIPAA-compliant faster and more affordably. That pivot got the team into Y Combinator last year and helped them raise their seed round from General Catalyst, FundersClub, Soma Capital, and others. The founders dropped out during their sophomore year in 2023. What started with HIPAA quickly expanded. 'As our customer base grew, they started asking for support with other frameworks: SOC 2, PCI, GDPR, ISO, basically the whole alphabet soup of compliance,' Kocalar narrated. Compliance paperwork can be necessary in everything from launching products to closing enterprise deals. But instead of driving growth, its manual work can become a bottleneck. 'Compliance frameworks are standardized. Businesses aren't,' says CEO Kaushik. 'That mismatch is why traditional software breaks down and teams fall back to duct-taped workflows across email, Slack, and shared drives.' Delve replaces that busywork with AI agents that run in the background (after integrating with customers' tools) like internal team members. These agents collect evidence, write reports, update audit logs, and track configuration changes across fragmented systems, automating compliance workflows in real time. Kocalar says compliance is just the wedge into broader back-office operations. Long-term, the AI startup wants to automate a billion hours of other work — eventually expanding into adjacent areas like cybersecurity, risk, and internal governance. Insight Partners' interest reflects this roadmap. 'Since compliance touches every part of how a business runs, from scaling operations to closing deals to building customer trust, modernizing this function will modernize the entire organization,' said Praveen Akkiraju, managing director at Insight. 'That's what makes Delve's approach so important.' Still, the startup won't be without competition. Several AI companies are emerging with agents to automate business workflows. In addition, larger AI labs like OpenAI are releasing general-purpose agents capable of performing complex tasks. That said, Kocalar says these developments are a validation, not a threat, to Delve's business. She points to the company's domain depth in contrast to more general-purpose agents. 'We're positioning ourselves to improve as AI advances and labs roll out more sophisticated agentic technologies. But what truly sets us apart is the deep, domain-specific knowledge we're building into the platform,' she said. 'Compliance is always shifting as new regulations emerge and existing ones evolve, with companies interpreting them in different ways. That's where Delve stands out.' Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-06-2025
- Health
- Business Wire
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
BOSTON--(BUSINESS WIRE)-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. "Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not and speed is critical' said Brad Murray, chief executive officer of Delve Bio. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. 'This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup,' said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. 'This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections.' The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? 'These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical,' said Brad Murray, chief executive officer of Delve Bio. 'We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need.' Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit
Associated Press
07-05-2025
- Health
- Associated Press
New Data Show Delve Bio's Metagenomic Platform Accurately Identifies Viruses and Their Subtypes With a Single Test
BOSTON--(BUSINESS WIRE)--May 7, 2025-- Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data showing that its groundbreaking infectious disease test, Delve Detect, is also capable of viral subtyping for select pathogens from sequence data analyzed through its proprietary bioinformatics pipeline, Delve Decide. The data will be presented at the Pan American Society for Clinical Virology (PASCV) Annual Meeting on May 8, 2025, in Clearwater, Florida. 'Identifying a pathogen is only the first part of the story. Knowing detailed information about the virus can signal to a physician whether a patient's infection is linked to an outbreak, carries unusual risks, or requires a change in management – crucial information when treating a patient with serious infections,' said Brian O'Donovan, Ph.D., head of bioinformatics at Delve Bio. 'Our study demonstrates mNGS has the potential to provide this information as part of routine testing, eliminating the need for sequential testing and subtyping that may delay patient care.' In the study, sequencing data generated by Delve Detect were compared to a specialized database of reference genomes. The study determined viral subtypes and phylogenetic classifications delivered by the Delve Decide bioinformatics platform across a number of viruses, including St. Louis encephalitis virus, enterovirus, West Nile virus, varicella-zoster virus and HIV, and described concordance with independent testing methods. 'Metagenomics is a game-changer for diagnosing infectious diseases, delivering meaningful, detailed information about the cause of a patient's infection through a single, straightforward test,' added Steve Miller, M.D., Ph.D., chief medical officer at Delve Bio. 'This study demonstrates that Delve Detect can deliver information that can impact management based on viral subtyping information and improve patient care.' The data will be presented at the meeting in poster No. 31, Rapid, Simultaneous Viral Pathogen Detection, Subtyping and Strain Differentiation Through Unbiased Metagenomic Sequencing With Delve Detect CSF on May 8 at 2:45 p.m. The study is part of the company's overall presence at the meeting, which also includes a presentation titled Metagenomic Next Generation Sequencing for CNS Infection by Delve co-founder Charles Chiu, M.D., Ph.D., professor of laboratory medicine and medicine/infectious diseases at University of California San Francisco (UCSF) today, Wednesday, May 7, at 6 p.m. Delve Detect was built on technology developed at UCSF, which is exclusively licensed to Delve Bio. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on CONTACT: Company ContactAmy Wong Senior Director of Marketing and Business Development, Delve Bio Email:[email protected] ContactJulie McKeough 42 North for Delve Bio Email:[email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA MASSACHUSETTS INDUSTRY KEYWORD: AIDS HEALTH INFECTIOUS DISEASES GENETICS HEALTH TECHNOLOGY BIOTECHNOLOGY SOURCE: Delve Bio, Inc. Copyright Business Wire 2025. PUB: 05/07/2025 07:32 AM/DISC: 05/07/2025 07:31 AM
BBC News
13-04-2025
- General
- BBC News
Restoration of RAF West Raynham will support veterans
A former RAF station headquarters is being restored to help support veterans in West Raynham closed in 1994 and its buildings became derelict until the Veterans' Service took over the building in have begun to restore the Grade II listed 1930s block and surrounding gardens, which are now used to help reduce social isolation and provide Delve, chair of trustees of the Veterans' Central, said: "We were looking for a veterans' hub, somewhere where veterans can come together for a breakfast, work together and socialise, removing social isolation and giving a sense of purpose." Mr Delve, who served as an RAF navigator on the Canberra and Tornado aircraft, said he and other volunteers at the RAF Marham heritage centre decided to restore the West Raynham station headquarters."Once it closed it went into a ten year period of care and maintenance, which meant no care and no maintenance, so all the buildings and the base started deteriorating," he said."Thirty years on it's been overgrown, things stolen and broken windows - that was the condition of what was a very important airfield in Norfolk for many years."When we first opened the door in late 2022, putting the live and dead animals to one side; the broken glass and water running down the walls, the veterans went: 'This is really good. We can do this', and in March 2023 we started." 'It's about people' Mr Delve estimated that some 26,000 hours of volunteer labour put the group six months ahead of what he said would be a seven-year project, transforming buildings and clearing gardens that had been 12ft (3.6m) high with he said they relied heavily on volunteers for labour and local businesses with materials, including a new kitchen and a greenhouse provided by firms that operate on part of the West Raynham average working day would see between 15 and 20 volunteers on site - and about a third had no military connection but wanted to join the team. He said he "got to know a lot of the old boys and girls from way back" through his interest as a squadron historian."I found their stories very interesting and had a passion for RAF history," he added."But [it is] the people involved - it's not about aeroplanes or buildings, it's about people. It's very much a people-driven project to make it work. "One of our aims is to give veterans a purpose, a reason to get up that day, go and do something, work with a team, have a bit of banter and a few slices of cake and a couple of cups of tea and feel you've achieved something with the day instead of sitting there doing nothing."The other is social isolation, so we do a monthly breakfast and a monthly lunch for veterans and they are all free at the point of delivery. "We are very lucky that local companies are starting to sponsor those lunches and breakfasts." Follow Norfolk news on BBC Sounds, Facebook, Instagram and X.
